Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07376889 · ClinicalTrials.gov registry record · Phase 4
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
A Phase 4 study, sponsored by Intermountain Health Care.
- Not yet
- Registry status
- Phase 4
- Development phase
- 2,096
- Enrollment target
NCT07376889: Clinical Trial Phase 4 study, sponsored by Intermountain Health Care.
NCT07376889 is a Phase 4 study that has not yet begun recruiting, run by Intermountain Health Care. The registered enrollment target is 2,096 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (305% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07376889, a Phase 4 study, has not yet begun recruiting, sponsored by Intermountain Health Care.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,096 participants
- Enrollment target
Study Summary
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
Primary Outcome
The DOOR ordinal scale includes four possible outcomes: treatment failure, infectious complications, antibiotic-associated adverse events and death. The ordinal scale comprises five levels: levels 1-4 are defined by survival at 30 days and the presence of either none, one, two or three of three possible outcomes; level 5 indicates death before 30 days. A DOOR analysis estimates the probability that overall outcomes in any given subject in one group are overall superior to those in a random subje
Interventions
- DRUG Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- DRUG Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
- DRUG Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- DRUG Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,096 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2029-01 |
| Phase | Phase 4 |
What is known before NCT07376889 opens enrollment
NCT07376889 is an interventional study that assigns participants to a tested intervention. Its 2,096 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (305% higher).
The record links to 0 conditions, and to 4 interventions - of which Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) is the first listed.
NCT07376889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07376889 about?
NCT07376889 is a clinical study titled "Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia". The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which a...
What is the current status of trial NCT07376889?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 2,096 participants. The study started on 2026-02-01. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07376889?
The interventions under investigation include: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (DRUG), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (DRUG), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (DRUG), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (DRUG).
Who is sponsoring clinical trial NCT07376889?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07376889's enrollment target sits among peer trials
2,096 34th of 2000 higher than 1,967 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI